Nexavar's domination of HCC set to continue
This article was originally published in Scrip
Nexavar will remain unchallenged in the foreseeable future as the first-line standard-of-care therapy for advanced hepatocellular cancer (HCC) as there are no potential first-line competitors in the late-stage development pipeline. In addition, Nexavar's commercial potential in the adjuvant setting, where it is currently in Phase III testing, is greater than other pipeline therapies, according to analysis from Datamonitor Healthcare.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.